A controlled trial of ambroxol in chronic bronchitis.
Ambroxol is a mucolytic agent which is widely used in chronic bronchitis in Europe. We conducted a double-blind randomized controlled trial of ambroxol vs matched placebo in 90 patients with chronic bronchitis and difficulty clearing secretions. It was concluded that there was no advantage to taking ambroxol.
Guyatt
G H
GH
Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada.
Townsend
M
M
Kazim
F
F
Newhouse
M T
MT
D000551:Ambroxol / Q000627:therapeutic use*; D001964:Bromhexine / Q000031:analogs & derivatives*; D001991:Bronchitis / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005100:Expectorants / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011897:Random Allocation; D012129:Respiratory Function Tests
D005100:Expectorants; D000551:Ambroxol; D001964:Bromhexine